Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $96.38 in the prior trading day, Amedisys Inc (NASDAQ: AMED) closed at $95.96, down -0.44%. In other words, the price has decreased by -$0.44 from its previous closing price. On the day, 0.72 million shares were traded. AMED stock price reached its highest trading level at $96.43 during the session, while it also had its lowest trading level at $95.56.
Ratios:
Our goal is to gain a better understanding of AMED by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.06 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.35. For the most recent quarter (mrq), Quick Ratio is recorded 1.29 and its Current Ratio is at 1.29. In the meantime, Its Debt-to-Equity ratio is 0.38 whereas as Long-Term Debt/Eq ratio is at 0.32.
Truist Downgraded its Buy to Hold on June 07, 2023, while the target price for the stock was maintained at $97.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 08 ’25 when Guidroz Allyson sold 374 shares for $96.00 per share. The transaction valued at 35,904 led to the insider holds 8,114 shares of the business.
Guidroz Allyson bought 374 shares of AMED for $35,853 on May 08 ’25. On Mar 04 ’25, another insider, Guidroz Allyson, who serves as the Chief Accounting Officer of the company, sold 2,041 shares for $92.03 each. As a result, the insider received 187,833 and left with 8,761 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMED now has a Market Capitalization of 3149368832 and an Enterprise Value of 3441704192. As of this moment, Amedisys’s Price-to-Earnings (P/E) ratio for their current fiscal year is 35.51, and their Forward P/E ratio for the next fiscal year is 18.67. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 7.43. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.33 while its Price-to-Book (P/B) ratio in mrq is 2.63. Its current Enterprise Value per Revenue stands at 1.451 whereas that against EBITDA is 14.1.
Stock Price History:
The Beta on a monthly basis for AMED is 0.90, which has changed by -0.013264775 over the last 52 weeks, in comparison to a change of 0.1185931 over the same period for the S&P500. Over the past 52 weeks, AMED has reached a high of $98.95, while it has fallen to a 52-week low of $82.15. The 50-Day Moving Average of the stock is 0.56%, while the 200-Day Moving Average is calculated to be 3.01%.
Shares Statistics:
The stock has traded on average 393.48K shares per day over the past 3-months and 552560 shares per day over the last 10 days, according to various share statistics. A total of 32.82M shares are outstanding, with a floating share count of 31.92M. Insiders hold about 2.75% of the company’s shares, while institutions hold 90.89% stake in the company. Shares short for AMED as of 1749772800 were 1965438 with a Short Ratio of 5.00, compared to 1747267200 on 2024273. Therefore, it implies a Short% of Shares Outstanding of 1965438 and a Short% of Float of 6.0900003.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
